Welcome to our dedicated page for Klaviyo SEC filings (Ticker: KVYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Klaviyo, Inc. (NYSE: KVYO) files a range of reports and disclosures with the U.S. Securities and Exchange Commission that shed light on its business, governance, and financial performance. This page aggregates those SEC filings so investors can review how the company describes its B2C CRM platform, subscription-based SaaS model, AI capabilities, and key operating metrics in official documents.
Among the most informative filings for Klaviyo are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detailed discussions of revenue, expenses, customer trends, and risks, as well as explanations of non-GAAP measures such as non-GAAP gross profit, non-GAAP operating income, and free cash flow. These reports also define operational metrics like customers, customers generating over specified annual recurring revenue thresholds, and dollar-based net revenue retention rate, and explain how management uses them to evaluate growth.
Current reports on Form 8-K give more timely insight into specific events. In 2025, Klaviyo used 8-K filings to announce quarterly results, share Black Friday–Cyber Monday data, post an investor day presentation, disclose an underwriting agreement for a secondary offering by selling stockholders, and describe leadership and governance changes, including the appointment of a co-Chief Executive Officer and amendments to its bylaws to allow for up to two Chief Executive Officers.
Investors can also review exhibits attached to these filings, such as employment agreements, compensation arrangements, equity award intention letters, and underwriting agreements, to better understand executive incentives, severance terms, and capital markets activity. Insider transaction reports on Form 4, when filed, provide additional visibility into equity ownership changes by directors and officers. With AI-powered summaries and search, this filings page helps users interpret lengthy documents, follow how Klaviyo’s disclosures evolve over time, and quickly locate information on topics such as executive compensation, stock-based awards, performance metrics, and material agreements.
Andrew Bialecki, CEO and director of Klaviyo, Inc. (KVYO), reported transactions dated 09/23/2025. The filing notes the acquisition of 211,358 shares of Series A Common Stock pursuant to conversion of Series B Common Stock and the sale of 181,553 shares at a weighted average price of $35.52 (sales priced between $35.025 and $36.02) plus an additional sale of 29,805 shares at a weighted average price of $35.01 (sales priced between $35.00 and $35.02). The transactions were effected under a Rule 10b5-1 trading plan adopted May 20, 2025. Footnotes identify several trust holdings for which the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
Klaviyo, Inc. filed a current report to notify investors that it has posted an updated investor presentation on its investor relations website in connection with its September 25, 2025 Investor Day event. The presentation covers the company’s business strategy, market opportunity, financial performance and guidance, and long-term outlook.
The materials are provided as a Regulation FD disclosure and are furnished, not filed, meaning they are intended to share information broadly with the market without being incorporated into other securities law filings unless specifically referenced.
Insider transactions by Klaviyo director and 10% owner Ed Hallen on 09/15/2025: The filing reports multiple sales and a gift under a Rule 10b5-1 plan adopted June 12, 2025. Mr. Hallen sold 22,224 shares of Series A common stock from direct holdings at a weighted-average $31.65 per share and 67,524 shares from holdings attributed to Hodgkins Trust at a weighted-average $31.73 per share, with sale prices in reported ranges. He also made a bona fide gift of 20,260 shares to a donor-advised fund. After these transactions, beneficial ownership reported is 702,216 shares (indirect) via Hodgkins LLC and related entities.
Andrew Bialecki, Klaviyo, Inc. Chief Executive Officer and a >10% owner, reported transactions in the company’s common stock executed under a Rule 10b5-1 trading plan. On 09/16/2025 the reporting person converted 226,382 shares of Series B common stock into Series A common stock and sold a total of 226,382 Series A shares in two blocks: 140,921 shares at a weighted average price of $32.71 and 85,461 shares at a weighted average price of $31.76. The Form 4 lists various indirect holdings through trusts and shows transfers and ownership details for those trusts. The filing was submitted by an attorney-in-fact.
Luciano Fernandez Gomez, Interim Executive Officer and director of Klaviyo, Inc. (KVYO) reported a securities transaction dated 09/15/2025. The filing shows an award of 100,597 restricted stock units (RSUs) under the issuer's 2023 Stock Option and Incentive Plan, recorded as an acquisition at $0. The RSUs vest in full on November 15, 2025, subject to continued service. After the reported transaction the reporting person beneficially owns 127,385 shares equivalent, consisting of 20,968 shares of Series A Common Stock and 106,417 unvested RSUs. The Form 4 was submitted via attorney-in-fact Landon Edmond and signed on 09/17/2025.
Stephen Eric Rowland, President and officer of Klaviyo, Inc. (KVYO), reported voluntary sales of Series A common stock on 09/15/2025 under a Rule 10b5-1 trading plan adopted on 11/22/2024. The filing shows two disposal entries: 6,905 shares sold at a weighted-average price of $31.90 per share (transactions ranged $31.43–$32.27), and 200 shares sold at $31.24. After these sales the reported beneficial ownership is shown as 438,821 and 438,621 shares respectively. The filing discloses that the total reported holdings consist of 129,070 issued shares and 309,551 unvested restricted stock units convertible into common shares upon vesting.
Klaviyo, Inc. (KVYO) notice reports a proposed sale of 7,105 common shares through Morgan Stanley Smith Barney with an aggregate market value of $221,604.95, and lists total common shares outstanding of 116,897,730. The shares were acquired as Restricted Stock Units on 08/15/2025. The filer also disclosed three recent 10b5-1 sales by the same person totaling 21,263 shares on 06/16/2025, 07/15/2025 and 08/18/2025 with combined gross proceeds shown. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Klaviyo, Inc. (KVYO) filed a Form 144 reporting a proposed sale of 89,748 Series A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $2,845,870.50. The notice lists the shares as founders' shares acquired from the issuer on 09/25/2012 and indicates the original acquisition was recorded as compensation. The filing shows 116,897,730 shares outstanding, and the approximate sale date is 09/15/2025. No securities were reported sold by the holder in the past three months. The filer affirms they are unaware of any undisclosed material adverse information.
A Klaviyo insider disclosure shows CFO Amanda Whalen effected share conversions and a small sale under a 10b5-1 plan on 09/12/2025. The report states the Reporting Person converted 11,204 shares of Series B common stock into Series A common stock and acquired 11,204 Series A shares. Separately, 15,000 shares of Series A were sold at a weighted-average price of $31.50 per share, reducing reported beneficial ownership to 481,719 shares. Holdings include 42,687 Series A shares and 439,032 unvested RSUs under the 2023 plan, plus 224,101 Series B shares and 184,375 RSUs under the 2015 plan that are referenced in footnotes.
Ed Hallen, a director and reported 10% owner of Klaviyo, Inc. (KVYO), reported transfers on 09/11/2025. The filing shows a total of 990,000 shares of the issuer's common stock moved the same day: 200,000 shares of Series A Common Stock were transferred to Hodgkins Trust and 790,000 shares to Hodgkins LLC, both described as for estate planning purposes and for no consideration. The report also shows the Reporting Person held 990,000 shares of Series B Common Stock (convertible into Series A) and discloses the conversion feature. The Form 4 was signed by an attorney-in-fact on 09/12/2025.